Abstract
Editors’ Note: In this editorial, Dr Pfeffer was invited to comment on the recent controversy of efficacy and harm of erythropoietinstimulating agents for treatment of anemia of chronic kidney disease. The editors consider the discussion by Dr Pfeffer on the conduct of these trials to be relevant to trials of other therapies in nephrology, such as those for phosphorus binding agents, for example the DCOR (Dialysis Clinical Outcomes Revisited) study presented elsewhere in this issue of AJKD (pp. 362 and 445).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of kidney diseases : the official journal of the National Kidney Foundation
Paper Title
Journal
Date
